File:Dddt-7-729Fig1.jpg

From WikiProjectMed
Jump to navigation Jump to search

Original file(703 × 629 pixels, file size: 120 KB, MIME type: image/jpeg)

This file is from a shared repository and may be used by other projects. The description on its file description page there is shown below.

Summary

Description
English: Sulfatide metabolic pathway.

Notes: The figure shows the biosynthetic pathways of sulfatide, the sphingolipid that accumulates during metachromatic leukodystrophy MLD. The specific enzymes described in each step of the pathway are in italics. The rounded boxes depict the products or substrates of the reactions. The green shaded square shapes show different therapeutic approaches for MLD treatment. Two current substrate reduction therapies for another lysosomal disease (Gaucher disease) are also shown: N-Butyldeoxynojirimycin (NB-DNJ) miglustat (Zavesca®, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland), and eliglustat tartrate. Both of these small molecules competitively inhibit ceramide glucosyltransferase.

Abbreviations: ASA, arylsulfatase A; EET, enzyme enhancement therapy; ERT, enzyme replacement therapy; Gal, galactose; HSCT, hematopoietic stem cell transplantation; Glc, glucose; SGal-Glc-cer, sulfo-galactose-glucosylceramide; MLD, metachromatic leukodystrophy; SRT, substrate reduction therapy.
Date
Source https://pubmed.ncbi.nlm.nih.gov/23966770/
Author Shilpa A Patil , Gustavo H B Maegawa

Licensing

English: This file is licensed CC BY-NC 3.0

This file was uploaded with UploadWizard.

File history

Click on a date/time to view the file as it appeared at that time.

Date/TimeThumbnailDimensionsUserComment
current23:38, 6 January 2024Thumbnail for version as of 23:38, 6 January 2024703 × 629 (120 KB)Ozzie10aaaaUploaded a work by Shilpa A Patil , Gustavo H B Maegawa from https://pubmed.ncbi.nlm.nih.gov/23966770/ with UploadWizard

The following page uses this file:

Metadata